Candidiasis is the most common opportunistic fungal infection in HIV patients. The aims of this study were to identify the prevalence of carriers of Candida, Candida species diversity, and in vitro susceptibility to antifungal drugs. In 297 HIV/AIDS patients in Baja California, Mexico, Candida strains were identified by molecular methods (PCR-RFLP) from isolates of oral rinses of patients in Tijuana, Mexicali, and Ensenada. 56.3% of patients were colonized or infected with Candida. In Tijuana, there was a significantly higher percentage of carriers (75.5%). Out of the 181 strains that were isolated, 71.8% were Candida albicans and 28.2% were non-albicans species. The most common nonalbicans species was Candida tropicalis (12.2%), followed by Candida glabrata (8.3%), Candida parapsilosis (2.2%), Candida krusei (1.7%), and Candida guilliermondii (1.1%). Candida dubliniensis was not isolated. Two associated species were found in 11 patients. In Mexicali and Ensenada, there was a lower proportion of Candida carriers compared to other regions in Mexico and worldwide, however, in Tijuana, a border town with many peculiarities, a higher carrier rate was found. In this population, only a high viral load was associated with oral Candida carriers. Other factors such as gender, use of antiretroviral therapy, CD4
Introduction
Oral pharyngeal candidiasis (OPC) is the most common opportunistic infection found in patients infected with human immunodeficiency virus or acquired immunodeficiency syndrome (HIV/AIDS), found in up to 90% of cases. 1 It is one of the initial manifestations in this group of patients. HIV/AIDS individuals are predisposed to recurrent episodes of OPC, which increase in frequency and severity with the progression to AIDS. 1 Clinically, oral lesions are classified as pseudomembranous, erythematous, and angular cheilitis variants. These lesions can be painful and promote a reduction in food ingestion, a situation that further compromises the recovery of these patients. 2 The occurrence of OPC is strongly associated with the decline of CD4 + T lymphocytes (200 cells/ml), the presence of high viral load (HIV), and the progression of the disease (AIDS). 3 The implementation of antiretroviral therapy (highly active antiretroviral therapy [HAART] ) generates a suppression of viral replication and patients partially recover CD4+ T lymphocyte counts. Although the incidence and prevalence of opportunistic infections has declined globally due to the use of HAART, OPC remains the most common oral disease associated with HIV patients in most developing countries. 1 In HIV/AIDS patients, Candida albicans is the most frequent species isolated from clinical samples throughout the word. In recent decades, other Candida species have become more frequent, particularly those species with reduced sensitivity or greater resistance to commonly used antifungal agents. The change in frequency of emerging species has made drug resistance a greater problem. Therefore, identification at the species level is critical to intervention against this disease. OPC increases morbidity and reduces quality of life; a rapid diagnosis and species identification to design adequate therapy is required. Currently the most widely used presumptive identification methods in yeasts are based on the use of selective culture media with chromogenic substrates. However, for a more accurate Candida species identification, there are molecular methods that analyze the rRNA 25S gene-encoding region, as well as the use of restriction enzymes for RFLP analysis. 4 The difference in species prevalence in HIV/AIDS patients is related to geographical location. In some countries, C. parapsilosis is the second most common species, while in other countries, C. glabrata is the most frequent second to C. albicans. [5] [6] These data underlie the importance of local data on Candida epidemiology from each city and health-care center. The aim of this study is to determine the frequency and species diversity of Candida spp. isolated from clinical samples (oral rinses) of both symptomatic and asymptomatic HIV/AIDS patients, as well as to determine the in vitro antifungal drug susceptibilities of isolates under study in the three more important cities in the state of Baja California, Mexico.
Patients and methods

Study population
Two hundred and ninety-seven adults diagnosed as HIV or AIDS positive were included, 98 from Tijuana, 99 from 
Antifungal susceptibility testing
All Candida species isolated from HIV/AIDS patients, were investigated for their in vitro susceptibility to amphotericin B, nystatin, clotrimazole, miconazole, ketoconazole, fluconazole, and itraconazole. We used the agar diffusion method that yields a quantitative result (zone of inhibition) and a qualitative interpretation category (S = sensitive, DD = dose dependent, and R = resistant), according to breakpoints established by CLSI standard method for Antifungal disk diffusion susceptibility testing of Candida spp. [10] [11] The Neo-Sensitabs tablet assay was performed according to the manufacturer's instructions (Neo-Sensitabs user's guide; A/S Rosco Diagnostica, Taastrup, Denmark) and M44-A guidelines. [10] [11] Briefly, Mueller-Hinton agar supplemented with 2% dextrose and 0.5 μg/ml methylene blue (MGM; Hardy Diagnostics, Santa Maria, CA) was inoculated with an undiluted culture (0. were determined measuring the nearest whole millimeter at a point in which there was either a prominent reduction of growth or no visible growth.
Statistical analysis
Data were analyzed using the χ 2 independence test considering a significance level of P<.05. 
Results
We studied 297 patients diagnosed with HIV or AIDS in the three largest cities in the state of Baja California, Mexico (Tijuana, Mexicali and Ensenada); 225 (75.7%) were male and 72 (24.3%) were female, with a mean age of 39.9 ± 10.3 years (mean ± standard deviation) and a range between 19 and 82 years (41.0 ± 9.2 years for Tijuana, 37.8 ± 10.5 years for Mexicali and 40.8 ± 10.9 years for Ensenada). Of the 297 HIV/AIDS-positive patients investigated, 170 (57.4%) were positive for oral carriage of yeast. Table 2 ). The most common non-albicans species were C. tropicalis with 22 isolates (12.2%), C. glabrata with 16 isolates (8.3%), C. parapsilosis with 5 isolates (2.2%), C. krusei with 3 isolates (1.7%), and C. guilliermondii with 2 isolates (1.1%). We could not assign a specie name to two isolates (1.2%). C. dubliniensis was not isolated, as confirmed by additional PCR analysis of those samples positive for C. albicans. By city, Ensenada had the highest percentage of C. albicans isolates compared to the other two cities (P = .004) ( Figure 2 , Table 2 ). In Mexicali, we found six different species of Candida, while in Tijuana we isolated four. However, the largest number of C. non-albicans species was isolated from Tijuana (C. tropicalis and C. glabrata).
Out of the 170 Candida carriers, 159 (94.1%) had a single strain of Candida, and 11 (6.5%) had two strains in the oral cavity. The most frequent association was C. albicans + C. glabrata, found in five patients, followed by C. albicans + C. tropicalis and C. glabrata + C. tropicalis, which were found in two patients each. C. albicans + C. parapsilosis and C. albicans + C. guilliermondii were found in one patient (Table 2) . Table 3 shows the absolute and relative frequency of Candida carriers by city according to the use of antiretroviral therapy, viral load, CD4 + T lymphocyte count and time to diagnosis. Two hundred and forty-nine patients (83.8%) were treated with HAART, and 48 (16.2%) did not have any treatment; the use of antiretroviral therapy showed no association (P > .05). We found Candida carriers in 52.6% of the patients with CD4 + T lymphocyte counts <200 cells/ml, 58.0% with 200-500 cells/ml, and 60.0% with > 500 cells/ml. Statistical analysis showed no association between CD4 + counts and Candida colonization (P = .6). Viral load most influenced the prevalence of Candida in the oral cavity (P = .02). The time to diagnosis showed no association with Candida colonization (P > .05). Smoking and alcohol use did not show any difference (P>.05), except for alcohol consumption in the individuals in Mexicali, which presented a significantly higher rate of carriers (P = .04) ( Table 4) . We found 117 carriers (68.0%) without oral lesions (asymptomatic carriers), and 53 carriers (32%) were symptomatic. The most common signs were oral mucosa inflammation, ulcers, and white plaques. The lesions produced by the mycotic infection were associated with herpes virus sores. By Candida specie, we found that 28.1% of the C. albicans carriers had lesions, in C. glabrata and C. tropicalis carriers 44.4%, in C. parapsilosis carriers 33.3%, and there was no lesion in the C. guilliermondii carriers. Nevertheless, the differences in the rate of lesion by Candida specie was not statistically significant (P = .12). The C. albicans isolates were sensitive to all drugs tested (96.1-100.0%) while in the C. non-albicans isolates the sensitivity to antifungal drugs was between 60.0 and 94.0%. There were statistically significant differences between C. albicans and C. non-albicans species for all the azoles tested (P<.001) but not for the polyenes (P = .08) ( Table 5 ). C. glabrata and C. tropicalis were the species with the lower sensitivity rate (Table 6 ). Fluconazole and miconazole were the azoles with higher resistance rates.
Discussion
OPC prevalence varies in different geographical areas, depending on the characteristics of the populations. However, HIV/AIDS patients are particularly vulnerable to colonization and infection by different fungal species, especially from the Candida genus. A wide range of Candida spp. carriers exists in HIV/AIDS patients (up to 96.0%) in different world regions, [12] [13] [14] [15] while the healthy population rate is 10.0 to 68.0%. [16] [17] We studied Candida species colonization of the oral cavity in HIV/AIDS patients in the three major cities in the state of Baja California, Mexico. There was a global Candida carrier rate of 57.4%, however, in Tijuana a significantly higher rate was observed. The global Ensenada and Mexicali prevalence of 21 and Argentina (62.3%). 22 However, in Tijuana, the prevalence was higher, except compared to Switzerland and the United Kingdom. 16, 20 In other studies in Mexico, a carrier rate of 66.7% was found in Mexico City 23 which is higher than in Ensenada and
Mexicali, but lower than in Tijuana. There are also reports of a lower carrier rate in other cities (31.6%). 24 The differences between the three cities studied might be due to their demographic features, Tijuana and Mexicali are two US border cities and Ensenada is a port city, 100 Km from the border. Tijuana has a very cosmopolitan population of 5 million inhabitants, 25 with a large variable population of immigrants to the United States who travel from the southern part of Mexico and Central America. However, Mexicali has a stable population ∼1 million inhabitants, 25 and Ensenada has ∼0.5 million people. 25 In this study, no differences in Candida carriage were observed according to gender, as found in another study in Mexico. 23 However, in other studies a higher number of female carriers were identified in patients with iron deficiencies.
26-28
Candida albicans has been observed as the most common specie found in oral samples (60-80%) in apparently healthy patients. 23, 29 In the three cities studied herein, our data is similar to other data reported, with 66.3% of C. albicans carriers in Tijuana, 72,8% in Mexicali, and 90.3% observed in Ensenada, although the latter value is higher than that reported by other authors in Mexico. 23 Nonalbicans species were found between 13.7 and 33.7% of the isolates. Their distribution was different in each of the cities studied, for example in Tijuana, C. tropicalis was the most common but not in Mexicali, where C. glabrata was found to be the most frequent strain. In Ensenada only one isolate each of C. glabrata, C. parapsilosis, C. krusei, and C. guilliermondii were found. Mexicali was the city with more species diversity. Tijuana and Mexicali had a higher rate of non-albicans species than other reports. [31] [32] None of the patients studied was a carrier of C. dubliniensis, a strain that has been isolated from patients with HIV/AIDS in other countries. 6, 10 Candida dubliniensis has not been isolated in this geographical region yet, although it has been isolated in Europe and North America in the last 20 years.
33-34
The variables associated with HIV/AIDS, such as the use of antiretroviral therapy, viral load, CD4+ T lymphocyte levels and time to diagnosis did not correlate with the frequency of carriage of Candida species. Only viral load (>100,000 viral copies) had an association with carriers. This finding was different to studies reported previously that have shown that high viral load was not associated with the presence of Candida species in the oral cavity. 23, [35] [36] As in other studies conducted over ten years, no association between antiretroviral therapy and the presence of oral Candida [29] [30] was found, in spite of the evolution of antiretroviral therapies that have been proven to be more effective. As for the levels of CD4+ T lymphocytes, our results are consistent with findings from other studies. 18, [37] [38] With regard to smoking, the highest percentage of Candida carriers was found among former smokers and smokers, although this was not significant. Other studies have also observed the influence of smoking to be the bearer of Candida, 12, 26, 39 but so far, there is no conclusive evidence for this association. Apparently there is great variability not only in carrier rate of Candida species and the proportion of species found, but also in relation to the different variables that might be associated (immune status, viral load, use of antiretroviral therapy, CD4+ T lymphocyte levels, smoking, alcohol consumption, and gender). These differences may be due to other factors intrinsically linked to populations in different geographic regions. This makes it very important to study the problem of Candida infections in different risk groups in various regions. Besides this, another factor that may be contributing to the variability of results is the types of methods used for both sampling and for the identification of cultured yeasts. In this study we used mouthwashes for obtaining isolates. This method has been shown to be the best method for detecting carriers. 12, 40 In accordance with the PCR-RFLP evidence, we are confident meaningful data has been obtained on the carrier state of oral candidiasis. 4 Although in general Candida spp. are susceptible to both azoles and polyenes, antifungal susceptibility varies significantly between C. albicans and C. non-albicans. Some C. non-albicans are inherently or secondarily resistant to azoles (10-75% 41 ); and resistance to polyenes is much less (5-20% [42] [43] [44] [45] ). Antifungal resistance has been related mainly to azole treatments in OPC in HIV/AIDS patients. [46] [47] [48] [49] [50] [51] [52] Fluconazole is the drug most used to treat OPCs in HIV/AIDS patients in Mexico, 53 and the increase of resistance to this triazole is becoming a difficult challenge. In HIV/AIDS oral Candida carriage, a prevalence of fluconazole-resistant C. albicans isolates was calculated to be between 12% and 22% in North American patients. [47] [48] [49] [50] Other studies have shown higher fluconazole susceptibility rates 93-97% and 3-7% DD susceptibility. 46, 52 Nevertheless, in the present study, we found DD susceptibility between 0.8% and 21.5% and resistance of 0.8-3.1% for C. albicans and DD susceptibility between 6.0% and 30.0% and resistance of 8.0-22.0% for C. non-albicans. The most resistant isolates were C. glabrata and C. tropicalis in the three cities, as has been reported before. 5, [54] [55] [56] Although primary resistance to fluconazole had been described for C. glabrata, acquired resistance seems to be more common.
The fact that C. glabrata is a haploid yeast, could promote the development of secondary resistance as well as crossresistance with other azoles such as itraconazole, ketoconazole, and voriconazole. [57] [58] [59] [60] However, fluconazole-resistant Candida species remain susceptible to other azoles, probably because there are different mechanisms of resistance to this group of drugs. [61] [62] [63] [64] [65] In this study, the prevalence of polyene-resistant Candida isolates was surprisingly low, for C. albicans only 0.8% had DD susceptibility to nystatin or amphotericin B. For C. non-albicans 6.0% were resistant to both antifungal drugs, similar to the findings in other populations where 0.4-4% of clinical isolates were classified as resistant. [42] [43] [44] [45] Amphotericin B is used as monotherapy in severe cases of OPC and candidemia, and in spite of it resistance to this drug remains rare. Its fungicidal effect might limit the selection of resistant mutants. However, some C. non-albicans show a slight decrease in susceptibility to amphotericin B as well as to nystatin, as shown in this study. [66] [67] [68] [69] [70] Other studies in severely compromised patients with fungemia have described polyene resistance in almost all Candida species (C. lusitaniae, C. rugosa, C. krusei, and C. guilliermondii, C. albicans, C. tropicalis, and C. glabrata). [41] [42] Previous reports on the mechanism of polyene resistance suggest that it is primarily associated with alterations in the sterol synthetic pathway, resulting in accumulation of intermediates with lower polyene affinity than ergosterol. 71 Nevertheless, the mechanism in our isolates has yet to be addressed.
In conclusion, this is the first study of Candida diversity in HIV/AIDS patients in northwestern Mexico. The differences in the frequency of Candida species between the three cities readily demonstrate the impact of geographical location. Further studies could clarify the resistance mechanisms to antifungal drugs of clinical isolates.
